Prosecution Insights
Last updated: November 04, 2026
Application No. 18/256,114

BENZOPYRAZOLE INHIBITORS OF SARM1

Non-Final OA §103
Filed
Jun 06, 2023
Priority
Dec 08, 2020 — provisional 63/122,682 +1 more
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Disarm Therapeutics Inc.
OA Round
3 (Non-Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
846 granted / 1143 resolved
+14.0% vs TC avg
Strong +31% interview lift
Without
With
+31.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
68 currently pending
Career history
1197
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
16.5%
-23.5% vs TC avg
§102
20.2%
-19.8% vs TC avg
§112
49.7%
+9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1143 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/4/2026 has been entered. Status of Claims Claims 1, 5-7, and 9-16 are pending in the instant application. Claims 9-11 and 14-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 1, 5-7, 12, and 13 is contained herein. The search extended to cover species wherein R2 = phenyl and other variables as shown in amended claim 1. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 5/22/2026 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 8/4/2026. New Rejections Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 5-7, and 13 are rejected under AIA 35 U.S.C. 103(a) as being obvious over US Publication 2004/0127536. The claims may be drawn to a compound and compositions thereof wherein R1 is a 6-membered heteroaryl (e.g. pyridinyl), L = ethylene, and R2 = phenyl. US Publication 2004/0127536 teaches the following compound and compositions thereof (see example 180, [0907] and [0168] for compositions thereof): PNG media_image1.png 204 450 media_image1.png Greyscale wherein R1 is a 5-membered heteroaryl, L = ethylene, and R2 = phenyl. The difference between these compounds stem from variable R1 (5- versus 6-membered heteroaryl). However the document teaches that 5-membered and 6-membered heteroaryls are interchangeable (see when variable R2 is R4 at [0031],[0036] and is selected from heterocycle encompassing heteroaryls such as pyridyl at [0071-0074]. Thus the claimed compounds would have been considered obvious. Conclusion Claims 1, 5-7, and 13 are rejected. Claim 12 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN MCDOWELL/ Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jun 06, 2023
Application Filed
Jan 29, 2026
Non-Final Rejection mailed — §103
Apr 22, 2026
Response Filed
May 22, 2026
Final Rejection mailed — §103
Jul 21, 2026
Response after Non-Final Action
Aug 04, 2026
Request for Continued Examination
Aug 05, 2026
Response after Non-Final Action
Aug 11, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12753196
ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
3y 6m to grant Granted Oct 06, 2026
Patent 12753167
INTERMEDIATE OF BILIVERDIN, AND PREPARATION METHOD AND USE THEREOF
3y 3m to grant Granted Oct 06, 2026
Patent 12747223
N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES
3y 3m to grant Granted Sep 29, 2026
Patent 12741943
Sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate, its preparation and use
4y 0m to grant Granted Sep 22, 2026
Patent 12741959
Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host Disease
2y 6m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+31.2%)
2y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1143 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month